Janux Therapeutics, Inc.
corporate_fare Company Profile
Janux Therapeutics, Inc. (NASDAQ:JANX) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 11 items for JANX at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-09, rated 8/10. Across its 11 most recent items scored 7 or higher, the top rating is 9/10, with 6 rated 8 or above. Recent SEC coverage for JANX spans 8-K, 10-Q, 10-K.
Recent high-impact activity:
- JANX011 Hits Deep B-Cell Depletion With Only Grade 1 CRS in First Human Data
- Janux Q2 2026: $970.9M Cash, Pipeline Progress, JANX013 on Track for H2 Initiation
- Janux Reports $970.9M Cash, Pipeline Progress in Q2 Update
- Janux CMO Departs, Company Assures No Change to Development Plans
- Janux Therapeutics Announces Chief Medical Officer Departure
Financial Snapshot
Short Interest & Short Volume
7.98 days to coverFINRA reported short interest of 5,329,932 shares in JANX as of the October 30, 2026 settlement, a 0.1% increase from the prior period — about 8.0 days to cover at its recent average daily volume. On November 19, 2026, 43.7% of JANX volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.